Establishing the optimal dose of nitric oxide in acute vasoreactivity testing in patients with pulmonary hypertension with use of the Bronchial Control Treatment System (RCD code: II)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2015, Vol 2, Issue 4
Abstract
The key point in the diagnostic algorithm for pulmonary hypertension plays the pulmonary reactivity testing, the agent most frequently used in the test is inhaled nitric oxide (iNO). Various dosages of iNO were used in acute vasoreactivity testing so far, so we aimed to determine the most effective dose of iNO administered in the acute vasoreactivity testing. Ten consecutive patients was enrolled to the open label study. To assess the most effective dose of iNO increasing concentrations of iNO: 10 ppm, 20 ppm and 30 ppm were administered. In the study statistically significant reduction in mean pulmonary artery pressure after each dose of iNO as compared to baseline was found. There were no significant differences in mean pulmonary artery pressure between subsequent iNO doses (10 ppm vs. 20 ppm, 20 ppm vs. 30 ppm). Statistically significant reduction of systolic pulmonary artery pressure after iNO at the dose of 20 ppm as compared to a dose of 10 ppm was observed. No significant side effects during iNO administration were observed. We concluded that the dose of inhaled nitric oxide used in the acute vasoreactivity testing should not exceed 20 ppm, it is effective and safe dose.
Authors and Affiliations
Magdalena Kaznica-Wiatr, Maria Olszowska, Piotr Podolec
Keywords
Related Articles
- EP ID EP242019
- DOI 10.20418/jrcd.vol2no4.189
- Views 129
- Downloads 0
Brugada syndrome: 2017 update. (RCD code: V-1A.1)
N/A
Exercise capacity in adult patients after Fontan procedure. (RCD code: IV-5B.1)
Background: The aim of Fontan procedure is to restore a balance between pulmonary and systemic circulation and improve or nearly normalize arterial saturation in patients with functionally univentricular heart. Neverthel...
Left atrial myxoma as a cause of multiple cerebral microembolization (RCD code: VI‐1A.1)
We report a case of a 56-year-old female after breast cancer treatment, who was diagnosed with left atrial myxoma as a rare cause of cerebral and cerebellar stroke.JRCD 2017; 3 (5): 168–170
3rd Symposium on Rare Cardiovascular Diseases – ESC Amsterdam 2013: Chairperson’s Perspective
The 3rd Satellite Symposiumon Rare Cardiovascular Diseases, which was organized by the Krakow Center for Rare Cardiovascular Diseases, was officially included in the Program of the 2013 ESC Congress and was held in the E...
The 4th Conference of Working Group in Congenital Heart Diseases of Polish Society of Cardiology
Congenital heart disease (CHD) is the most common developmental anomaly and represents about 1% of all live-born children. Recent progress in cardiac surgery and pediatric cardiology has resulted in large numbers of adu...